Immunicum AB: Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)

Immunicum AB announced that it has been granted an orphan drug designation from the US FDA for ilixadencel in the treatment of GIST. This designation confirmed the need and potential for ilixadencel as a new treatments for patients with GIST, which is a rare and difficult to treat subgroup of cancers reffered to as soft tissue sarcoma.